Category: News & Research

  • Fake and Counterfeit Weight-Loss Drugs: How to Spot Them

    Fake and Counterfeit Weight-Loss Drugs: How to Spot Them

    In short: Counterfeit GLP-1 medicines are real and have reached the regular U.S. supply chain: the FDA has warned about fake Ozempic pens three times, in December 2023, April 2025 and December 2025, and seized thousands of units. Fakes may contain the wrong ingredient, the wrong amount or none at all, and FDA found counterfeit needles whose sterility could not be confirmed. The safest steps are to get a prescription, fill it at a state-licensed pharmacy, check the pen and carton before every use, and never buy “semaglutide” or “tirzepatide” sold without a prescription or “for research purposes”.

    This page explains the FDA alerts, how fake and illegally sold products differ from compounded medicines, and a checklist for spotting problems. Compounded semaglutide and tirzepatide are a separate topic with their own risks; our guide to compounded GLP-1s covers them. For the real medicine, see Ozempic and GLP-1 medications. Alerts were checked on fda.gov on October 7, 2026. This is general education: if you think your medicine may be fake, don’t use it, and contact your pharmacist or clinician.

    Counterfeit, illegal, compounded: three different problems

    • Counterfeit products pretend to be a brand-name medicine. The FDA says they “claim to be authentic, but could contain the wrong ingredients, contain too little, too much or no active ingredient at all or other harmful ingredients, and are illegal.”
    • Illegally sold products are sold without a prescription, often online, or labeled “for research purposes” or “not for human consumption”. The FDA has warned companies selling semaglutide, tirzepatide, retatrutide, survodutide and mazdutide this way. Some are counterfeit; none are FDA approved.
    • Compounded versions are made by pharmacies for individual prescriptions. They are legal in some circumstances but are not FDA approved, and the FDA has received reports of adverse events and dosing errors with them. They have their own page: compounded GLP-1s explained.

    The FDA’s counterfeit Ozempic alerts

    All three alerts involved the 1 mg Ozempic (semaglutide) injection pen, a diabetes medicine that is also widely used off label for weight. Each time, the FDA asked patients, pharmacies, wholesalers and health professionals to check the products they had received and not use, sell or distribute the ones described.

    FDA counterfeit Ozempic alerts, as of October 7, 2026

    1. December 21, 2023Thousands of units seized. Lot NAR0074 with serial number 430834149057. Needles, pen label, carton and leaflets were counterfeit; needle sterility could not be confirmed.
    2. April 14, 2025Several hundred units in the U.S. supply chain, seized April 9. Lot PAR0362 with serial numbers starting 51746517.
    3. December 5, 2025Dozens of units seized after Novo Nordisk alerted the FDA on November 18. Lot PAR1229, also a real lot number: on the fakes, the "EXP/LOT" text sits to the left of the date and lot, not above them.

    Two details are worth knowing. First, in the 2025 case the counterfeit lot number was also an authentic one, so a lot number on its own doesn’t prove a pen is real; the FDA pointed to the position of the printed text instead. The FDA added that patients who received lot PAR1229 through Novo Nordisk’s patient assistance program could keep using it, because those pens were authentic. Second, these fakes were found in the legitimate supply chain, not only on shady websites, which is why the FDA urges pharmacies to buy only from the manufacturer’s authorized distributors.

    The adverse events the FDA knew about were reassuring so far: in 2023 it was aware of five reports for the counterfeit lot, none serious and all consistent with Ozempic’s common side effects, and in both 2025 alerts the six reports for the lot did not appear to be linked to the counterfeit product. But testing of the seized pens was still underway in each case, so the contents were unknown at the time of the alerts.

    What researchers found when they bought “semaglutide” online

    In a pair of 2024 studies, Ashraf and colleagues searched Google and Bing for semaglutide sold without a prescription in July 2023. Of 317 links to online pharmacies, 134 (42.3%) led to illegal sellers. The team then tried to buy from six of them. The three sites selling prefilled Ozempic-style pens never delivered; instead they asked for extra “customs” payments of $650 to $1,200, which customs agencies confirmed were fraud. The three vials that did arrive were all judged probably substandard or falsified, contained endotoxin (a bacterial contaminant), and had semaglutide purity of only 7.7% to 14.4%, far below the 99% claimed on their labels.

    Semaglutide vials bought online without a prescription: purity claimed vs measuredValues in %
    Semaglutide vials bought online without a prescription: purity claimed vs measured
    ItemValue
    Purity claimed on label99%
    Highest purity measured14.37%
    Lowest purity measured7.70%

    Endotoxin was found in all three samples. The three prefilled pens ordered were never delivered (non-delivery scams).

    Source: Ashraf AR et al., Journal of Medical Internet Research 2024 (3 vials from illegal online pharmacies) (checked on October 7, 2026)

    Where fakes come from: buying online safely

    The National Association of Boards of Pharmacy (NABP), which accredits online pharmacies, reports that nearly 95% of websites offering prescription-only drugs operate illegally, and that 96% of the illegal online pharmacies it reviewed did not require a valid prescription. A website ending in .pharmacy has been accredited by NABP, and unlike a logo, that web address can’t be faked; NABP’s Safe Site Search tool lets you check any pharmacy website.

    Online pharmacy facts

    • Nearly 95%of websites offering prescription-only drugs online operate illegallyNABP
    • 96%of illegal online pharmacies NABP reviewed did not require a valid prescriptionNABP
    • 42.3%of online-pharmacy links found when searching for semaglutide led to illegal sellers (July 2023)Ashraf AR et al., JAMA Network Open 2024

    Checked on October 7, 2026

    The FDA’s BeSafeRx campaign lists the signs of a safe online pharmacy and the warning signs of an unsafe one:

    Likely safe if it…Possibly unsafe if it…
    Always requires a prescriptionDoesn’t require a prescription
    Gives a physical U.S. address and phone numberIsn’t licensed in the U.S. and by your state board of pharmacy
    Has a licensed pharmacist to answer questionsHas no licensed pharmacist
    Is licensed with a state board of pharmacyOffers prices that seem too good to be true
    Sends medicine that looks different, or arrives broken, damaged, in a foreign language, with no expiration date, or expired

    Telehealth programs can be a legitimate way to get a prescription, but check who prescribes and which pharmacy fills it; our telehealth weight-loss programs compared and telehealth weight loss guide explain what to ask. If cost is pushing you toward a cheap online source, look first at Ozempic cost, GLP-1 coverage and our cost hub.

    Pen and package checklist

    Check every new box before the first injection. Compare it with the patient leaflet and the photos in your manufacturer’s instructions, and with the pen you have used before.

    Before I use a new GLP-1 pen

    • ☐ It came from a state-licensed pharmacy, with a pharmacy label in my name
    • ☐ The carton is sealed, undamaged and printed in English, with an expiration date that hasn’t passed
    • ☐ The lot number and expiration date on the carton match the ones on the pen
    • ☐ The lot is not one named in an FDA counterfeit alert (NAR0074 with serial 430834149057; PAR0362 with serials starting 51746517; PAR1229 with “EXP/LOT” printed to the left of the date)
    • ☐ The pen label, colors, dose and needles look the same as the leaflet pictures and my previous pens
    • ☐ The medicine looks the way the leaflet describes
    • ☐ It is a pen or tablet approved in the U.S., not a powder vial sold online or “for research”
    • ☐ If anything looks off: don’t inject; call the pharmacy and the manufacturer

    From instatuck.com, checked against FDA alerts and BeSafeRx on October 7, 2026. Education only; not medical advice.

    Compounded products: a related warning

    The FDA’s page on unapproved GLP-1 drugs (content current as of October 1, 2026) reports that, as of May 31, 2026, it had received 990 reports of adverse events linked to compounded semaglutide and more than 730 linked to compounded tirzepatide, and that some reports involved dosing errors from measuring doses from vials. It also warns that some compounders have used salt forms, such as semaglutide sodium and semaglutide acetate, which are different active ingredients from the approved medicines, and notes one adverse event with a product labeled as compounded tirzepatide from a pharmacy that hadn’t actually made it. That last case is a reminder that fake “compounded” labels exist too.

    Misleading marketing: words to watch for

    Even legal sellers can blur the lines. On March 3, 2026, the FDA announced warning letters to 30 telehealth companies over false or misleading marketing of compounded GLP-1s. The problems it described included suggesting a compounded drug was the same as, or a generic version of, an FDA-approved medicine; implying the product was FDA approved or had been evaluated for safety and effectiveness; and branding compounded drugs with the telehealth firm’s own name so it wasn’t clear who actually made them. The FDA stressed that compounded drugs are not FDA approved and are not the same as generics, which do go through FDA approval.

    So when you shop for a program, be wary of phrases like “generic Ozempic”, “same as Wegovy” or “FDA-approved semaglutide” attached to a product that isn’t the brand-name pen or tablet. Ask plainly: is this the FDA-approved product, or a compounded one, and which pharmacy makes it? A trustworthy prescriber will answer without hesitation.

    If you think your medicine is fake

    1. Don’t use it. Keep the pen, carton and receipt.
    2. Call your pharmacy and the manufacturer to check the lot and serial number.
    3. Talk to your clinician about any symptoms, and about how to restart safely with a genuine supply.
    4. Report it to the FDA. Side effects and product problems go to MedWatch (online or by fax at 1-800-FDA-0178); websites selling suspect medicines can be reported to the FDA as well.

    The bottom line

    Fake GLP-1s have reached U.S. pharmacies, and illegal online sellers are common. A prescription, a state-licensed pharmacy and a quick check of every new box are your best protection. If you are just starting out, our questions to ask before starting a GLP-1 include where to fill the prescription, and our directory helps you find a provider who prescribes and follows up. And be just as wary of “GLP-1” supplements that promise the same effect; our “nature’s Ozempic” explainer explains why.

  • Weight-Loss News Roundup: October 2026

    Weight-Loss News Roundup: October 2026

    In short: No new weight-loss medicine was approved between mid-September and October 5, 2026, but a lot happened around the edges. New trial results for three investigational treatments (retatrutide, CagriSema and a combination called EloraTZP) were presented at the European diabetes meeting (EASD); the FDA announced charges in a counterfeit Ozempic case and warned about a weight-loss product with a hidden drug; and Medicare open enrollment starts October 15. Here is what each item means, and what it does not.

    Lake, autumn, wet dog, man's friend, rocky, game, retrieving, water, davos, animal, nature, on a walk, pure-breed dog
    Photo: pasja1000 / Pixabay

    We check every item against a primary source: the FDA, DailyMed, CMS, journals or ClinicalTrials.gov. Company press releases are labeled “company-reported”. Nothing here is advice for your own treatment; bring questions to your clinician. Earlier coverage lives in our research and news section.

    This month in numbers

    • -18.8%top-dose average weight change with investigational retatrutide in TRIUMPH-2 (adults with type 2 diabetes, 80 weeks)Bellido V et al., Lancet 2026
    • 367adults in the Phase 2b EloraTZP trial reported on September 30 (company-reported)Eli Lilly
    • Q4 2026when Novo Nordisk expects the FDA decision on CagriSemaNovo Nordisk
    • $50Medicare GLP-1 Bridge copay, available through December 31, 2027CMS

    Checked on October 6, 2026

    Approvals and regulatory

    LABEL CHANGE: Zepbound and Foundayo labels updated. The current Zepbound label on DailyMed (revised August 2026) was published on September 2, and the Foundayo label (published August 13) follows an FDA-approved Medication Guide update on August 4. Our medication pages are checked against these versions. Labels change for many reasons, from wording to new safety information, and our records note the version we read.

    PENDING: CagriSema. Novo Nordisk filed CagriSema (cagrilintide plus semaglutide) with the FDA in December 2025 and said on September 30 that it still expects a decision in the fourth quarter of 2026. It is not approved; our CagriSema explainer covers the trials, including the head-to-head trial in which it did not match tirzepatide.

    COMPOUNDING: FDA guidance updated October 1. The FDA refreshed its page on concerns with unapproved GLP-1 drugs. Its message is unchanged: compounded drugs are not FDA approved, and the semaglutide and tirzepatide shortages ended in 2025 and 2024. Its April 2026 proposal to exclude semaglutide, tirzepatide and liraglutide from the list of bulk ingredients that outsourcing facilities may use was still a proposal when we checked. Background: compounded GLP-1s.

    New studies

    INVESTIGATIONAL: Retatrutide in type 2 diabetes (TRIUMPH-2). Published in The Lancet and presented at EASD, this trial gave 1,152 adults with type 2 diabetes and a BMI of 27 or more one of three doses of retatrutide, a weekly injection that acts on GIP, GLP-1 and glucagon receptors, or placebo. Average weight change, counting everyone randomized, was -11.9%, -16.8% and -18.8% by dose vs -5.1% with placebo. Lilly reported that HbA1c fell by up to 1.6 points. What it means: retatrutide’s results hold up in people with diabetes, who usually lose less weight. What it doesn’t: retatrutide is not approved; Lilly says it plans to submit it to the FDA in the first quarter of 2027.

    TRIUMPH-2: average weight change by retatrutide dose (type 2 diabetes)Values in %
    TRIUMPH-2: average weight change by retatrutide dose (type 2 diabetes)
    ItemValue
    Placebo5.1%
    Retatrutide low dose11.9%
    Retatrutide middle dose16.8%
    Retatrutide high dose18.8%

    Percent of body weight lost; treatment-regimen estimand. Investigational drug, not FDA approved.

    Source: Bellido V et al., Lancet 2026 (TRIUMPH-2) (checked on October 6, 2026)

    INVESTIGATIONAL: EloraTZP, an amylin plus tirzepatide combination (company-reported). Lilly reported a 48-week Phase 2b trial in 367 adults with obesity or overweight and type 2 diabetes. The highest combination (eloralintide 9 mg with tirzepatide 15 mg) averaged -23.3% vs -14.8% with tirzepatide 15 mg alone and -3.0% with placebo, under an estimate that assumes everyone stayed on treatment. Stopping because of side effects ranged from 10.8% to 27.0% across combination arms vs 2.9% with tirzepatide alone. What it means: adding an amylin drug to tirzepatide added weight loss in this study. What it doesn’t: it is a mid-stage trial; Lilly plans Phase 3 by the end of 2026.

    EloraTZP Phase 2b: average weight change at 48 weeks (company-reported)Values in %
    EloraTZP Phase 2b: average weight change at 48 weeks (company-reported)
    ItemValue
    Placebo3%
    Tirzepatide 15 mg alone14.8%
    Eloralintide 3 mg + tirzepatide 5 mg13.2%
    Eloralintide 6 mg + tirzepatide 5 mg19.4%
    Eloralintide 6 mg + tirzepatide 10 mg19.9%
    Eloralintide 9 mg + tirzepatide 15 mg23.3%

    Efficacy estimand (as if all stayed on treatment). Adults with type 2 diabetes. Combinations are investigational; tirzepatide alone is approved as Zepbound and Mounjaro.

    Source: Eli Lilly press release, September 30, 2026 (checked on October 6, 2026)

    INVESTIGATIONAL: CagriSema data at EASD (company-reported). Novo Nordisk presented a 52-week brain-imaging study linking CagriSema to changed responses to high-calorie food cues, plus body-fat, organ-fat and bone findings from its REIMAGINE diabetes trials. Full papers were not yet published.

    STUDY: Foundayo in type 2 diabetes (company-reported). Lilly said ACHIEVE-4 showed Foundayo was non-inferior to insulin glargine, with a 16% lower risk of a combined measure of heart and stroke events (MACE-4). Foundayo is approved for weight management; type 2 diabetes is still an investigational use. See orforglipron for the molecule.

    How to read this month’s trial numbers

    Three things make conference headlines look more alike than they are. First, the estimand: TRIUMPH-2 counts everyone who was randomized (a “treatment-regimen” estimate), while the EloraTZP numbers assume everyone stayed on treatment (an “efficacy” estimate), which gives larger figures. Second, the population: all three September studies we covered were in people with type 2 diabetes, who usually lose less weight on these medicines than people without diabetes. Third, the stage: TRIUMPH-2 is a Phase 3 trial published in a peer-reviewed journal, while EloraTZP is a mid-stage Phase 2b study announced by the company. None of these numbers can be compared directly with each other or with an approved medicine’s label.

    For scale only: in their own placebo-controlled trials in people without diabetes, Wegovy averaged -14.9% at 68 weeks (STEP 1) and Zepbound 15 mg -20.9% at 72 weeks (SURMOUNT-1). Our Wegovy vs Zepbound page explains the one head-to-head trial between approved medicines.

    Where the approved options stand

    GroupApproved for weight (October 6, 2026)What changed this month
    Weekly GLP-1 and GIP/GLP-1 injectionsWegovy, Wegovy HD, ZepboundZepbound label version updated on DailyMed (September 2)
    Daily GLP-1 pillsWegovy tablets, FoundayoFoundayo diabetes data reported; diabetes use still investigational
    Daily injectionsSaxenda and generic liraglutide; Imcivree (rare conditions)No change found
    Other pillsQsymia, Contrave, orlistat (Xenical, Alli), short-term phentermineNo change found
    Under FDA reviewNone approved: CagriSema pendingDecision still expected in Q4 2026 (company)
    From DailyMed and Drugs@FDA, checked 2026-10-06. Full details: every FDA-approved weight-loss medication compared.

    Safety alerts

    SAFETY ALERT: Counterfeit Ozempic case. On September 29, the FDA announced that its investigation led to charges against two Indian nationals accused of distributing counterfeit Ozempic obtained from unauthorized sources in China between July 2023 and April 2024, with fake packaging, inserts, pen labels and needles. The FDA has issued public alerts about counterfeit Ozempic since December 2023.

    SAFETY ALERT: Hidden sibutramine in a weight-loss product. On September 15, the FDA warned consumers not to buy or use LUZE Fit Intensity, promoted for weight loss online and possibly in stores, because it contains sibutramine, a drug not listed on the label. The FDA says sibutramine can significantly raise blood pressure or heart rate, a serious risk for people with heart disease, heart failure, irregular heartbeat or stroke. Sibutramine was withdrawn from the U.S. market in 2010. Our supplements guide explains why products sold as supplements are not FDA approved.

    Prices and coverage

    PRICE/COVERAGE: Medicare open enrollment, October 15 to December 7. This is when people with Medicare can change plans for 2027. Separately, the CMS Medicare GLP-1 Bridge (July 1, 2026 to December 31, 2027) offers Wegovy (injection and tablets), Zepbound KwikPen and Foundayo for weight management for a $50 copay to people who meet its criteria. Our insurance guide explains the criteria in plain words.

    PRICE/COVERAGE: Self-pay prices as of October 6. NovoCare Pharmacy lists Wegovy pens at $349 a month ($199 for the first two fills of the lowest doses for new patients through December 31), Wegovy HD at $399 and Wegovy tablets at $149 to $299. Lilly lists Zepbound KwikPen at $299 to $449 and Foundayo at $149 to $349, by dose. Novo has also announced that Wegovy’s list price will drop to $675 a month from January 1, 2027. Details: cost hub and Wegovy cost.

    Maker self-pay prices per month on October 6, 2026 (USD)
    Maker self-pay prices per month on October 6, 2026 (USD)
    ItemLowHigh
    Foundayo$149$349
    Wegovy pens$199$349
    Wegovy HD$399$399
    Wegovy tablets$149$299
    Zepbound KwikPen$299$449

    Ranges are by strength. Prescription required; offers often exclude government insurance. Prices change; confirm before you plan.

    Source: NovoCare Pharmacy; Lilly Zepbound and Foundayo savings pages (checked on October 6, 2026)

    Industry and pipeline

    INDUSTRY: Novo licenses a once-weekly oral candidate. On September 29, Novo Nordisk announced an exclusive license to HRS-1596, a GLP-1/GIP dual receptor agonist from Hengrui Pharma designed as a once-weekly pill, for up to $2.6 billion including $300 million upfront. It is ready for Phase 1 trials, so any approval would be years away. Weekly pills would differ from today’s daily options; our oral GLP-1 guide explains the approved ones.

    What we updated on InstaTuck

    What’s coming next

    WhenWhat to watchStatus
    October 15 to December 7Medicare open enrollment for 2027 plansScheduled (Medicare.gov)
    November 14 to 17ObesityWeek 2026, National Harbor, Maryland: new trial results often appear hereScheduled
    November 2026TRIUMPH-5, retatrutide vs tirzepatide head-to-head: primary completion listed for this monthResults timing set by Lilly
    Q4 2026FDA decision on CagriSema expectedCompany expectation
    Q1 2027Lilly’s planned FDA submission for retatrutideCompany plan
    January 1, 2027Wegovy list price set to drop to $675 a monthCompany announcement
    Checked on 2026-10-06. Company dates can move.

    Looking for the bigger picture? Our what’s new in weight loss in 2026 piece sorts this year’s changes into proven, promising and hype, and the emerging medications page tracks every investigational candidate. For the approved options and how they work, start at the medications hub or the GLP-1 guide.